Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Rekombinanter TNF alpha (Infliximab Biosimilar) Antikörper

Reaktivität: Human FACS, in vivo Wirt: Maus Monoclonal cA2 unconjugated Recombinant Antibody
Produktnummer ABIN7200661
  • Target Alle TNF alpha (Infliximab Biosimilar) Produkte
    TNF alpha (Infliximab Biosimilar)
    Antikörpertyp
    Recombinant Antibody
    Reaktivität
    Human
    Wirt
    • 1
    • 1
    • 1
    Maus
    Klonalität
    • 3
    Monoklonal
    Konjugat
    • 3
    Dieser TNF alpha (Infliximab Biosimilar) Antikörper ist unkonjugiert
    Applikation
    • 3
    • 2
    • 2
    • 1
    Flow Cytometry (FACS), In vivo Studies (in vivo)
    Verwendungszweck
    Infliximab Biosimilar, TNF alpha Monoclonal Antibody
    Spezifität
    The monoclonal antibody Infliximab biosimilar specifically binds to the human TNF alpha.
    Produktmerkmale
    Recombinant Chimeric IgG1 Monoclonal Antibody.
    Aufreinigung
    Protein A affinity column
    Reinheit
    > 95% by SDS-PAGE under reducing conditions and HPLC.
    Sterilität
    0.2 μm filtered
    Endotoxin-Niveau
    < 1 EU per 1 mg of the protein by the LAL method.
    Immunogen
    The monoclonal antibody Infliximab biosimilar was produced in the Infliximab biosimilar CHO stable cell line.
    Klon
    CA2
    Isotyp
    IgG1 kappa
  • Applikationshinweise
    ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Infliximab.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    1 mg/mL
    Buffer
    PBS, pH 7.4, no stabilizers or preservatives.
    Konservierungsmittel
    Without preservative
    Handhabung
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    Lagerung
    -20 °C
    Informationen zur Lagerung
    12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
    Haltbarkeit
    12 months
  • Target
    TNF alpha (Infliximab Biosimilar)
    Abstract
    TNF alpha (Infliximab Biosimilar) Produkte
    Synonyme
    DIF antikoerper, TNF-alpha antikoerper, TNFA antikoerper, TNFSF2 antikoerper, tumor necrosis factor antikoerper, TNF antikoerper
    Substanzklasse
    Biosimilar
    Hintergrund
    Infliximab, a chimeric anti-TNF-α monoclonal antibody, is used to treat psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Infliximab interferes TNF-α from binding to its receptor in the cell.

    Mainly produced by activated macrophages (M1), Tumor necrosis factor (TNF, cachexin, cachectin, tumor necrosis factor alpha, TNFα) plays important roles in the regulation of autoimmune reaction.
Sie sind hier:
Kundenservice